Disc Medicine's CEO reviews recent EHA data, including learnings about clinical endpoints from the company's lead GlyT1 program

blonca9
Jul 1, 2024
1 min read

John Quisel describes how bitopertin aims to reduce PPIX, a photosensitiser that makes it painful for patients when exposed to light. Plus, learnings about clinical endpoints from the company's P2 experience, and highlights on two hepcidin programs.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Disc Medicine's CEO reviews recent EHA data, including learnings about clinical endpoints from the company's lead GlyT1 program

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight